US pulls GSK’s COVID drug as omicron sibling dominates cases
New study suggests base editing may be an effective one-time, durable treatment for inherited retinal degeneration
5 April 2022Researchers identify an immunotherapy target to combat glioblastomas
5 April 2022US pulls GSK’s COVID drug as omicron sibling dominates cases
GlaxoSmithKline’s IV drug for COVID-19 should no longer be used because it is likely ineffective against the omicron subvariant that now accounts for most U.S. cases, federal health regulators said Tuesday.
